Professional Documents
Culture Documents
Typically 2 5 year retest dates, so long stability studies Typically not claimed to be sterile so no micro complications Straight forward protocols and reports But, all auditors ask to look at stability programs
They expect to see a well run compliant program Samples pulled and testing done on time SOPs, investigations, training etc
API GMPs
ICH Q7 : Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (2000)
APIs from chemical synthesis, extraction, recovery from natural sources, cell culture/fermentation, or combination of these
Common practice is to use retest dates, not an expiration date (Section 11.6) API Stability (Section 11.5):
First three commercial lots used to establish retest or expiry date, then one batch per year are stability tested Guidance on testing intervals The test procedures used in stability testing should be validated and be stability indicating
Guidelines
Core guide (ICH) for EU, USA & Japan
Other countries have similar
So follow ICH but check for any differences if supplying APIs to nonEU/US/Japan
ICH No Q1A(R2) Q1B Q1C Q1D Q1E Q1F Guideline Stability Testing of New Drug Substances and Products Photostability of New Drug Substances and Products Stability Testing for New Dosage Forms Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products Evaluation of Stability data Stability Data Package for Registration Applications in Climatic Zones III and IV
API Stability 2012 4
ICH Q1A(R2)
APIs = Drug Substances = Active Substances Note ICH Q1A(R2) is applicable to New drug substances, so should it apply to Existing drug substances? Yes, for example:
EMEA (CPMP/QMP/122/02) :Guideline on Stability Testing: Stability of Existing Active Substances and Related Finished Products This Guideline is similar to ICH Q1A(R2)
API Stability 2012 5
Stability Conditions
Study Long term Intermediate Accelerated General Case Storage Condition Climatic Zones III & IV (ICH Q1F) (ICH Q1A(R2) 25C 2C/60% RH 5% RH or 30C 2C/65% RH 5% RH 30C 2C/65% RH 5% RH 30C 2C/65% RH 5% RH 40C 2C/75% RH 5% RH 40C 2C/75% RH 5% RH
If use 30 C, then do not have intermediate condition For stable APIs, use 30 C to minimise samples on stability WHO Technical Report No 953, Annex 2 summarises the requirements of individual countries
API Stability 2012 6
Consider the risk that the processing change could have on the long term stability before undertaking additional stability testing
Stability SOP
Typically follows ICH Q1A(R2) Also, the Stability SOP will define:
Max time between manufacture date and placing samples in chamber to initiate programs
Window to pull samples from chambers and window to test after the pull date, e.g.:
Test Date (Months) < 1 month 1 M to < 3M 3M to < 6M > = 6M > 24 M Window to pull samples Exact day + 3 days + 7 days + 14 days
API Stability 2012
Testing frequencies,
Typically every 3 months or less for first year (follow guidleines)
Typically
Appearance or Description Assay Related Substances or Impurities Solvent or water content
Will consider stability indicating methods later
API Stability 2012 10
Stability Protocol
Need a protocol to initiate stability program records:
Defines conditions, specification, test methods, testing frequency; Manufacturing date and Approval date Time zero results (i.e. lot release data) Packaging
11
Consider an annual summary report for each API to collate results from all active programs When analysing data:
The data may show so little degradation it is normally unnecessary to go through the formal statistically analysis..
API Stability 2012 12
Thus HPLC methods are best Do not assume an USP or EP/BP method is stability indicating you need to determine if it is or not
Especially old methods unlikely to be suitable
API Stability 2012 13
Active substance peak is spectrally pure by Photo Diode Array analysis Degradants are assayed by the method
Thus the method will show when degradation is occurring
The HPLC method then relies upon a drop in assay and an increase in impurities to indicate that the API is degrading over time on stability
Relying upon seeing a trend in lower assay only may not confirm trend until many data points are available due to method variability
API Stability 2012
14
Stress Conditions
As per ICH Q1A
The nature of the stress testing will depend on the individual drug substance and the type of drug product involved On solid API
So use scientific common sense when designing experiments Photo degradation as per ICH Q1B, 1.3 Million lux hours Thermal, not more than 100 C Humidity, where appropriate Oxidation, e.g. add hydrogen peroxide and heat if needed Acid & Base hydrolysis, e.g. acidic or basic solutions heated to 70 C for4 hours
In solution
Evaluate Results
Assess active substance PDA peak purity Compare the control to the degradation sample
For solution experiments, before adding acid, base or peroxide Compare to any known impurity standards available
18
Stability Chambers
Critical Laboratory Equipment, so full GMP required:
Qualification: temperature and humidity mapping to ensure all parts of the chamber is within spec. Calibrate temperature and humidity probes Log the temperature and humidity conditions Consider power backup Investigate/document any significant outages
API Stability 2012 19
Evaluated to confirm your stability programs are being conducted at the correct conditions Frequency
Outcome
ICH does not specify, USP<1150> for drug products suggests weekly, so you need to define: Consider daily evaluation, review data monthly and perform the calculations Short term spikes in conditions will be compensated for Document the MKTs in a report which then supports the individual stability program reports
API Stability 2012 20
API Intermediates
ICH Q7 is silent on requiring stability testing of intermediates, but this is normally done on a more limited basis Typically undertake testing programs to test initial lots to establish retest date, without further annual testing. Retest date are normally shorter than APIs Intermediates may be damp, not dried, so these are more likely to degrade, thus more critical to undertake these studies
API Stability 2012 21
References/Links
ICH Guidelines
http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html Regulatory/Human Medicines/Scientific Guidelines/Quality/Stability http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000361.jsp&mid=WC0b0 1ac0580028eb1
WHO Report 953 Stability Testing of Active Pharmaceutical Ingredients and Finished Products, 2009, updated 1 Dec 2010
http://apps.who.int/medicinedocs/en/m/abstract/Js19133en/ New and Revised Monograph Guidance http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/chapter1.pdf
USP:
22